Pfizer and Glenmark Pharmaceuticals Ltd. have partnered to launch abrocitinib, a unique oral advanced systemic treatment for moderate-to-severe atopic dermatitis in India. Developed by Pfizer, abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India and is approved by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other regulatory agencies.
When launched in India, it will be co-marketed under the brand names JABRYUS® and CIBINQO® by Glenmark and Pfizer respectively. This collaboration combines the expertise of the companies to offer a groundbreaking treatment for moderate-to-severe AD, with improved efficacy and oral convenience to patients. Meenakshi Nevatia, Country President and Managing Director of Pfizer India stated, “Our collaboration with Glenmark will help leverage the collective strengths and capabilities of our organizations to make this breakthrough therapy available to patients and physicians across our country.”
Atopic dermatitis is a chronic skin disease causing inflammation and skin barrier defects. Itching in moderate-to-severe AD disrupts daily life, impacting social interactions, work productivity, and overall well-being. Abrocitinib, a Janus kinase 1 inhibitor, provides rapid itch relief, sustained disease control, and improved quality of life.